Lebrikizumab in the personalized management of asthma

References

• RobinsonDSHamidQYingSPredominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthmaN Engl J Med19923262983041530827
   PubMed Web of Science ®Google Scholar
• HoltPGMcCaubusCStumblesPASlyPDThe role of allergy in the development of asthmaNature1999402B12B1710586890
   PubMed Web of Science ®Google Scholar
• BarnesPJImmunology of asthma and chronic obstructive pulmonary diseaseNat Rev Immunol20088318319218274560
   PubMed Web of Science ®Google Scholar
• SzeflerSMartinRKingTSignificant variability in response to inhaled corticosteroids for persistent asthmaJ Allergy Clin Immunol2002109341041811897984
   PubMed Web of Science ®Google Scholar
• BatemanEDBousheyHABousquetJCan guideline-defined asthma control be achieved?: the gaining optimal asthma control studyAm J Respir Crit Care Med2004170883684415256389
   PubMed Web of Science ®Google Scholar
• AndersonGEndotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous diseaseLancet200837296431107111918805339
   PubMed Web of Science ®Google Scholar
• HumbertMBeasleyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy200560330931615679715
   PubMed Web of Science ®Google Scholar
• ThomsonNCChaudhuriROmalizumab: clinical use for the management of asthmaClin Med Insights: Circ Respir Pulm Med20126274022745565
   PubMedGoogle Scholar
• ThomsonNChaudhuriRSpearsMEmerging therapies for severe asthmaBMC Med20119110221896202
   PubMed Web of Science ®Google Scholar
• HolgateSTTrials and tribulations in identifying new biologic treatments for asthmaTrends in Immunol201233523824622436378
   PubMed Web of Science ®Google Scholar
• GrunigGWarnockMWakilAERequirement for IL-13 independently of IL-4 in experimental asthmaScience19982825397226122639856950
   PubMed Web of Science ®Google Scholar
• Wills-KarpMLuyimbaziJXuXInterleukin-13: central mediator of allergic asthmaScience1998282225822619856949
   PubMed Web of Science ®Google Scholar
• HersheyGKKIL-13 receptors and signaling pathways: an evolving webJ Allergy Clin Immunol2003111467769012704343
   PubMed Web of Science ®Google Scholar
• HowardTDWhittakerPAZaimanALIdentification and association of polymorphisms in the Interleukin-13 gene with asthma and atopy in a Dutch populationAm J Respir Cell Mol Biol200125337738411588017
   PubMed Web of Science ®Google Scholar
• HunninghakeGMSoto-QuirosMEAvilaLPolymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhoodJ Allergy Clin Immunol20071201849017561245
   PubMed Web of Science ®Google Scholar
• SahaSKBerryMAParkerDIncreased sputum and bronchial biopsy IL-13 expression in severe asthmaJ Allergy Clin Immunol2008121368569118328894
   PubMed Web of Science ®Google Scholar
• BarnesPJAdcockIMGlucocorticoid resistance in inflammatory diseasesLancet200937396781905191719482216
   PubMed Web of Science ®Google Scholar
• SidhuSSYuanSInnesALRoles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthmaProc Nat Acad Sci U S A2010107321417014175
   PubMed Web of Science ®Google Scholar
• WoodruffPGBousheyHADolganovGMGenome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroidsProc Nat Acad Sci U S A2007104401585815863
   PubMed Web of Science ®Google Scholar
• TakayamaGArimaKKanajiTPeriostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signalsJ Allergy Clin Immunol200611819810416815144
   PubMed Web of Science ®Google Scholar
• HaldarPPavordIDNoneosinophilic asthma: a distinct clinical and pathologic phenotypeJ Allergy Clin Immunol200711951043105217472810
   PubMed Web of Science ®Google Scholar
• DouwesJGibsonPPekkanenJPearceNNon-eosinophilic asthma: importance and possible mechanismsThorax200257764364812096210
   PubMed Web of Science ®Google Scholar
• WenzelSEAsthma: defining of the persistent adult phenotypesLancet2006368953780481316935691
   PubMed Web of Science ®Google Scholar
• WoodruffPGModrekBChoyDFT-helper Type 2-driven inflammation defines major subphenotypes of asthmaAm J Respir Crit Care Med2009180538839519483109
   PubMed Web of Science ®Google Scholar
• DrazenJMA step toward personalized asthma treatmentN Engl J Med2011365131245124621991898
   PubMed Web of Science ®Google Scholar
• CorrenJLemanskeRFHananiaNALebrikizumab treatment in adults with asthmaN Engl J Med2011365121088109821812663
   PubMed Web of Science ®Google Scholar
• KioiMSeetharamSPuriRKN-linked glycosylation of IL-13Rα2 is essential for optimal IL-13 inhibitory activityFASEB J200620132378238017023392
   PubMed Web of Science ®Google Scholar
• ScheerensHArronJRSuZPredictive and pharmacodynamic biomarkers of interleukin-13 blockade: effect of lebrikizumab on late phase asthmatic response to allergen challengeJ Allergy Clin Immunol2011127Suppl 2AB164
   Web of Science ®Google Scholar
• McClintockDCorrenJHananiaNLebrikizumab, an anti-IL-13 monoclonal antibody, reduces severe asthma exacerbations over 32 weeks in adults with inadequately controlled asthmaAm J Respir Crit Care Med2012185A3959
   Google Scholar
  Proceedings of the American Thoracic Society International Conference2012 May 18–23San Francisco, CA, USA
   Google Scholar
• ScheerensHArronJChoyDMosesovaSLalPMatthewsJLebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostinAm J Respir Crit Care Med2012185A3960
   Google Scholar
  Proceedings of the American Thoracic Society International Conference2012 May 18–23San Francisco, CA, USA
   Google Scholar
• CorrenJCytokine inhibition in severe asthma: current knowledge and future directionsCurr Opin Pulm Med201117293321330823
   PubMed Web of Science ®Google Scholar
• EliasJALeeCGIL-13 in asthma: the successful integration of lessons from mice and humansAm J Respir Crit Care Med2011183895795821498814
   PubMed Web of Science ®Google Scholar
• MayRDMonkPDCohenESPreclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthmaBr J Pharmacol2012166117719321895629
   PubMed Web of Science ®Google Scholar
• PiperEBrightlingCNivenRA phase 2 placebo-controlled study of tralokinumab in moderate-to-severe asthmaEur Respir J Epub June 27, 2012
   Web of Science ®Google Scholar
• GauvreauGMBouletL-PCockcroftDWEffects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthmaAm J Respir Crit Care Med201118381007101421057005
   PubMed Web of Science ®Google Scholar
• WenzelSWilbrahamDFullerRGetzEBLongphreMEffect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studiesLancet200737095961422143117950857
   PubMed Web of Science ®Google Scholar
• WenzelSIndPOtulanaBBleeckerEKunaPYenYInhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthmaProceedings of the European Respiratory Society Annual Congress2010 Sept 18–20Barcelona, Spain
   Google Scholar
• PurcellRLockeyRImmunologic responses to therapeutic biologic agentsJ Investig Allergol Clin Immunol2008185335342
   PubMed Web of Science ®Google Scholar
• WenzelSEAsthma phenotypes: the evolution from clinical to molecular approachesNat Med201218571672522561835
   PubMed Web of Science ®Google Scholar
• Flood-PagePSwensonCFaifermanIA study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthmaAm J Respir Crit Care Med2007176111062107117872493
   PubMed Web of Science ®Google Scholar
• HaldarPBrightlingCEHargadonBMepolizumab and exacerbations of refractory eosinophilic asthmaN Engl J Med20093601097398419264686
   PubMed Web of Science ®Google Scholar
• GreenRHBrightlingCEMcKennaSAsthma exacerbations and sputum eosinophil counts: a randomised controlled trialLancet200236093471715172112480423
   PubMed Web of Science ®Google Scholar